Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Key Highlights
- ➤Iovance (IOVA) will webcast positive lifileucel TIL data in previously treated nonsquamous mNSCLC
- ➤Webcast will detail IOV-LUN-202 Phase 2 registrational cohort results
- ➤Company will update precision-based medicine opportunities for its TIL platform in mNSCLC
- ➤Amtagvi is FDA-approved for previously treated advanced melanoma in three global markets
PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, October 29, 2026 at 8:30 a.m. ET to highlight positive results for one-time lifileucel TIL therapy from the IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous mNSCLC and an update on precision-based medicine opportunities for the TIL platform in mNSCLC.
To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/qtiiq5pi. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year.
Get started
Create a free account to read the full story.